|
PHF5A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.37549971412909E-11 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
9.341700E-02 |
| Stage1-vs-Stage3 |
1.904520E-03 |
| Stage1-vs-Stage4 |
4.02959999999952E-05 |
| Stage2-vs-Stage3 |
7.695400E-01 |
| Stage2-vs-Stage4 |
1.563790E-01 |
| Stage3-vs-Stage4 |
1.167630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.9925999739101E-09 |
| Normal-vs-Asian |
1.00840003014468E-09 |
| Caucasian-vs-AfricanAmerican |
7.417900E-02 |
| Caucasian-vs-Asian |
4.060000E-01 |
| AfricanAmerican-vs-Asian |
4.850000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
2.252400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
8.620000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.250000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.021800E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.238600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.618100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.237420E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.943920E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.941640E-01 |
| Classical-VS-Follicular |
4.434200E-02 |
| Classical-VS-Other |
8.186000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
7.686400E-01 |
| Tall-VS-Other |
8.725400E-01 |
| Tall-VS-Normal |
1.74416037168612E-12 |
| Follicular-VS-Other |
7.446800E-01 |
| Follicular-VS-Normal |
<1E-12 |
| Other-VS-Normal |
4.232400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.29181126801359E-13 |
| N0-vs-N1 |
7.437200E-01 |
|
|
